RapidIdentity is the most complete Identity and Access Management (IAM) platform available, giving organizations greater security, increased business agility, and lower costs of identity and access management. With RapidIdentity, organizations can transform identity and access management across all users—including employees, contractors, partners, and vendors. Improve productivity and collaboration by giving the right people, the right access, from anywhere—for the time needed.

Identity Automation offers streamlined identity management software that improves organizational security, increases productivity, and reduces IT costs. Its flagship product, RapidIdentity, gives organizations the ability to provide employees and external users fine-grained time-based access to on-premises and cloud-based data and systems.

✓ Passive technology, no installed software agents to manage, ideal for medical devices ✓ Utilizes research based on deep experience in medical device use and design and strong understanding of cybersecurity principles & practices, along with Artificial Intelligence (AI), machine learning and proprietary algorithms, to perform deep packet analysis of device data traversing the network ✓ Supports several use cases across Inventory, Cybersecurity and Operational Management with an expanding platform roadmap to meet additional operational and strategic organizational requirements ✓ Integrates with an organization’s supporting IT/Security platforms, i.e. CMMS, SIEM, Vulnerability Scanners, Network firewalls and network access controls to support the health system overall IT Security and Risk management programs and maximize existing platform tools and investments Visibility of critical information across organizational disciplines: Clinical Team, IS Team, Risk Managers ✓ External Connections: finding the bad actors ✓ IT Services protocols: i.e. SMB, RDP, FTP ✓ Anomalies: real time Network Traffic Analysis (NTA) ✓ Forensics: data flow, protocols, and traffic stats ✓ FDA Recall: linked to FDA device database ✓ Supported by Asimily researchers and analysts